The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04351347 |
Recruitment Status :
Recruiting
First Posted : April 17, 2020
Last Update Posted : March 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID | Drug: Ivermectin | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment |
Actual Study Start Date : | June 16, 2020 |
Estimated Primary Completion Date : | December 1, 2030 |
Estimated Study Completion Date : | December 1, 2030 |

Arm | Intervention/treatment |
---|---|
Experimental: Ivermectin
Ivermectin alone in larger doses
|
Drug: Ivermectin
ivermectin |
No Intervention: Standard treatment
Standard of care treatment
|
- Number of patients with improvement or died [ Time Frame: 1 month ]The number of patients with improvement or death

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with covid 19
Exclusion Criteria:
- Allergy or side effects to treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04351347
Contact: Sherief Abd-Elsalam, ass. prof. | 00201147773440 | sheriefabdelsalam@yahoo.com |
Egypt | |
Tanta University | Recruiting |
Tanta, Egypt, 35111 | |
Contact: Sherief Abd-Elsalam |
Principal Investigator: | sherief Abd-Elsalam, Ass. Prof. | Tanta University - Faculty of Medicine |
Responsible Party: | Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University |
ClinicalTrials.gov Identifier: | NCT04351347 |
Other Study ID Numbers: |
ivermecin covid |
First Posted: | April 17, 2020 Key Record Dates |
Last Update Posted: | March 10, 2021 |
Last Verified: | March 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ivermectin Antiparasitic Agents Anti-Infective Agents |